Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks. RESULTS: At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P < 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P < 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P < 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion. CONCLUSIONS: Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EMPA-REG BP trial, empagliflozin reduced mean 24 hour ambulatory systolic BP by approximately 3-4 mmHg after 12 weeks, 16 with consistent reductions irrespective of the number of background BP lowering drugs.17”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [16]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · cited 1×
“Randomized controlled trials have shown reductions in major cardiovascular events when SBP was lowered to ,150 mmHg and DBP was lowered to # 85 mmHg in patients with diabetes (23,24).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cited by
Items 301–400 of 505
NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY
Rajagopal, R., & McGill, J. B. (2024) · Retina · doi:10.1097/iae.0000000000004252 · Cited by 11
SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis
Goodarzi, S., Abhari, F. S., Azarinoush, G., Rafiei, M. A., Yousefian, H., Heidari, E., Ekramipour, E., Mirzaei, A., Namakin, K., & Shafiee, A. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03768-z · Cited by 11
Ohashi, N., Aoki, T., Matsuyama, T., Ishigaki, S., Isobe, S., Fujikura, T., Hashimoto, T., Tsuriya, D., Morita, H., Kato, A., et al. (2020) · Medical Science Monitor · doi:10.12659/msm.926086 · Cited by 11
Wang, J., She, Q., & Du, J. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01430-9 · Cited by 11
Emphysematous Kidney Related to the Use of Empagliflozin in a Diabetic Woman
Echeverria, P., Saa, J., & y Miño, L. P. (2023) · AACE Clinical Case Reports · doi:10.1016/j.aace.2023.06.001 · Cited by 11
Ferdinand, K. C., SEMAN, L. J., & Salsali, A. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1405800 · Cited by 11
Self-citationHopf, M., Kloos, C., Wolf, G., Müller, U. A., & Muller, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040571 · Cited by 11
Chan, A. T. P., & Tang, S. C. W. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.285 · Cited by 11
Saha, S., & Saha, S. (2020) · PubMed Central · Cited by 11
Gliflozins in hypertension: basic mechanisms and clinical insights
Rieg, T., Liu, R., & Staruschenko, A. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00119.2025 · Cited by 10
Chinnadurai, R., Wu, H. H. L., Abuomar, J., Rengarajan, S., New, D. I., Green, D., & Kalra, P. A. (2023) · World Journal of Nephrology · doi:10.5527/wjn.v12.i5.168 · Cited by 10
Raja, A., Dogar, M., Raja, S., Shuja, M. H., Amin, S. B., Khelani, M., Fatima, U., Soomro, A., Habiba, A., Mustafa, I., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04412-x · Cited by 10
“Despite concerns about orthostatic hypotension in specific contexts, the overall evidence suggests that dapagliflozin does not significantly increase the risk of hypotension [40–42].”
Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus
Chauhan, S., Manov, A. E., Dhillon, G. S., & Shah, P. (2023) · Cureus · doi:10.7759/cureus.33892 · Cited by 10
Guo, Z., Wang, L., Yu, J., Wang, Y., Yang, Z., & Zhou, C. (2023) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01504-6 · Cited by 10
“SGLT-2 inhibitors can affect hemodynamics and significantly reduce blood pressure [13, 19].”
BackgroundSugawara, M., Fukuda, M., Sakuma, I., Wakasa, Y., Funayama, H., Kondo, A., Itabashi, N., Maruyama, Y., Kamiyama, T., Utsunomiya, Y., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01438-w · Cited by 10
The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Dhindsa, D. S., Sandesara, P. B., & Shapiro, M. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00160 · Cited by 10
“The possible explanations for these observations include osmotic diuresis leading to improved cardiac hemodynamics by reduction in left ventricular afterload, lowering of body weight due to calorie and fluid losses, and lowering of blood pressure (19, 20).”
BackgroundAn evaluation of empagliflozin and it’s applicability to hypertension as a therapeutic option
Herat, L. Y., Matthews, V. B., Magno, A. L., Kiuchi, M. G., Carnagarin, R., & Schlaich, M. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1751815 · Cited by 10
“As summarized in Table 2, similar findings have been reported for the most widely prescribed SGLT2 inhibitors Empagliflozin [67], Dapagliflozin [70], and Canagliflozin [71].”
BackgroundRomera, I., Gomis, R., Crowe, S., de Pablos-Velasco, P., Aranda, U., García, A., Kis, S. G., & Naderali, E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.016 · Cited by 9
Ji, L., Mishra, M., & Geest, B. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041092 · Cited by 9
Effects of Empagliflozin on Vascular and Skeletal Mineralization in Hyperlipidemic Mice
Kalanski, S., Pradhan, S., Hon, A., Xia, Y., Safvati, N., Rivera, J. C., Lu, M., Demer, L. L., & Tintut, Y. (2024) · Vascular Pharmacology · doi:10.1016/j.vph.2024.107376 · Cited by 9
Gherbon, A., Frandeș, M., Dîrpeş, D., Timar, R. Z., & Timar, B. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01326-8 · Cited by 9
Aronow, W. S., & Shamliyan, T. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.43 · Cited by 9
“Efficacy Moderate-quality evidence suggests that empagliflozin reduces all-cause mortality (7,11,40,44,46,47,49-61) and increases the rates of diabetes control without increasing the risk of serious adverse effects and hypoglycemia when compared with placebo in adults with type 2 diabetes (Table 1) (50,51,70).”
BackgroundSkelin, M., Javor, E., Lucijanić, M., Lucijanić, T., Jakupović, L., & Rahelić, D. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13274 · Cited by 9
Alqudsi, M., Velez, J. C. Q., & Navarrete, J. E. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000865 · Cited by 9
“Interestingly, patients with baseline 24-h BP 130/ 80 mmHg had greater decline of BP, whereas empagliflozin dosage and number of antihypertensive agents at baseline did not make a difference [21,22].”
BackgroundSabirov, I. S., Murkamilov, I. T., & Fomin, V. V. (2021) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2021-10-3-79-89 · Cited by 9
Ren, B., & Chen, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142450 · Cited by 9
Dhindsa, D. S., Mehta, A., Sandesara, P. B., Thobani, A., Brandt, S., & Sperling, L. S. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1197-6 · Cited by 9
Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
Chrysant, S. G., & Chrysant, G. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2057949 · Cited by 8
Kasama, S., Masuyama, T., Uemura, S., Sato, Y., Hiramitsu, S., Masuda, I., Yamamoto, K., Komatsu, S., Anzai, T., Nishimura, K., et al. (2019) · Circulation Reports · doi:10.1253/circrep.cr-19-0049 · Cited by 8
“23 Given that SGLT2-I have a blood pressure-lowering effect without affecting heart rate, 24 there is a possibility that sympathetic nerves are not activated by SGLT2-I.”
Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
Ahmann, A. (2015) · Drugs in Context · doi:10.7573/dic.212288 · Cited by 8
“Empagliflozin has also been associated with significant reductions of BP in patients with T2DM and hypertension [36].”
SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos, P. I., Divani, M., Eleftheriadis, T., Mertens, P. R., & Liakopoulos, V. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180524114033 · Cited by 8
Alemohammad, F., Abdollahi, S., Raoufi, Z., & Moghimipour, E. (2025) · Journal of Polymers and the Environment · doi:10.1007/s10924-025-03604-6 · Cited by 7
“These drugs can be categorized into five groups: insulin-releasing agents (e.g., sulfonylureas and glinides), inhibitors of glu - cose absorption, insulin sensitizers, incretin-based therapies (e.g., DPP4 inhibitors and GLP-1 receptor agonists), and SGLT-2 inhibitors[ 10 ].”
SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10087 · Cited by 7
Chen, G., Zhang, D., Du, A., Zhang, Y., Zhang, Y., Zhang, L., Zang, S., Liu, X., Wang, Z., Zhen, H., et al. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2432 · Cited by 7
“Furthermore, in addition to reducing hyperglycemia, empagliflozin improved blood pressure in patients with T2DM.(23) Two TEAEs of hypotension occurred in this study, indicating that empagliflozin had the efficacy of reducing blood pressure in both healthy people and patients with T2DM.”
BackgroundInfluentialSGLT2 inhibitors might halt progression of diabetic nephropathy
Yamout, H., & Bakris, G. L. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.109 · Cited by 7
Pollak, P. T., Herman, R., & Feldman, R. D. (2017) · Clinical and Translational Science · doi:10.1111/cts.12442 · Cited by 7
Piccirillo, F., Lanciotti, M., Nusca, A., Frau, L., Spanò, A., Liporace, P., Ussia, G. P., & Grigioni, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052103 · Cited by 6
Design and Evaluation of Instant Release Buccal Films of Empagliflozin: A Statistical Approach
Salawi, A., Tabassum, N., Zaman, M., Khan, M. A., Siddique, W., Alshamrani, M., Alsalhi, A., Albariqi, A. H., & Alshamrani, A. A. (2025) · ACS Omega · doi:10.1021/acsomega.5c02082 · Cited by 6
Hu, Q., Yang, S., Zhang, B., & Su, N. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01950-y · Cited by 6
“This phenomenon was detected in half of these studies, which compared the effects of different doses on lowering sUA [27, 31, 35, 41, 43, 44, 48, 51, 60, 62, 64, 66, 69].”
Alamdari, N. M., Barghaman, M., Roshanravan, N., Mobasseri, M., Tutunchi, H., Baharami, A., Aliasgarzadeh, A., & Sadra, V. (2025) · BMC Research Notes · doi:10.1186/s13104-025-07214-2 · Cited by 6
Mitochondrial dysfunction in hypertension: mechanistic pathways and therapeutic implications
Tian, J., Yi, L., Lu, Y., Kou, Y., Zhang, L., Jin, P., Wang, X., Wu, T., Yang, X., Wang, Y., et al. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01813-9 · Cited by 6
“Empagliflozin, a widely used SGLT2 inhibitor, lowers blood pressure (Tikkanen et al. 2015) and reduces Cardiac microvascular endothelial cell (CMEC) damage in diabetes by inhibiting Drp1 phosphorylation at Ser616.”
The changing therapeutic armamentarium for patients with type 1 diabetes
Comee, M., & Peters, A. L. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000239 · Cited by 6
Shigiyama, F., Hiruma, S., Hisatake, S., Shiraga, N., Ikeda, T., Hirose, T., & Kumashiro, N. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0640-4 · Cited by 6
Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
Hage, L. E., Kashyap, S. R., & Rao, P. (2019) · Journal of Primary Care & Community Health · doi:10.1177/2150132719895188 · Cited by 6
Bhagya, G., Namini, M. T., Girish, B. S., & Srinivasan, R. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.274 · Cited by 6
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Gómez‐Huelgas, R., de Lucas, M. D. G., Polo, L. M., Aguilar, J. M. V., & Muñoz, J. E. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0280-1 · Cited by 6
Puli, K., & Vanjari, N. K. (2019) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20195271 · Cited by 6
Kallistratos, M. S., Konstantinidis, D., Dimitriadis, K. S., Sanidas, E. A., Katsi, V. K., Androulakis, E. S., Vlachopoulos, C. V., Toutouzas, K. P., Kanakakis, J., Sideris, S. K., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.08.008 · Cited by 7
Dapagliflozin combination therapy in type 2 diabetes mellitus
Yacoub, T. G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1111119 · Cited by 6
“of CV events.[107,108,124] The blood pressure-reducing effects of SGLT2 inhibitors were further evaluated in a randomized controlled trial using dapagliflozin 10 mg/day, which was found to be as effective in reducing 24-h ambulatory SBP (–5.”
BackgroundDalan, R. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000201 · Cited by 6
Furuki, T., Kobayashi, K., Toyoda, M., Hatori, N., Sakai, H., Sato, K., Miyakawa, M., Tamura, K., & Kanamori, A. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14084 · Cited by 6
Exploring the Link between Cardiorenal and Metabolic Diseases
D’Marco, L., & Checa-Ros, A. (2023) · Healthcare · doi:10.3390/healthcare11212831 · Cited by 6
Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis Masked by Urinary Tract Infection
Chauhan, S., Díaz, V., Ogbu, I. R., Sanchez, J. R. P., Manov, A. E., & Shah, P. (2024) · Cureus · doi:10.7759/cureus.66408 · Cited by 5
“Studies have shown that SGLT-2 inhibitors have demonstrated efficacy in reducing both systolic and diastolic blood pressure, as evidenced by findings from trials such as EMPA-REG BP [8].”
BackgroundBlood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Siddiqi, A. K., Khan, M. S., Kulkarni, A., Hall, M. E., Böhm, M., Díez, J., & Butler, J. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01342-7 · Cited by 5
“…DBP. Compared with placebo, office SBP/DBP reductions range from 1.2/0.6 mmHg to 8.6/4.2 mmHg [36 , 37 , 40 , 44 , 45 , 48 , 49 , 52 , 54 , 57–59], while 24-hour ambulatory SBP/DBP reductions range between 2.4/0.7 mmHg and 7.7/2.9 mmHg depending on drug type and dosage [ 37 , 38 , 40 , 48 , 54].”
InfluentialDey, A. K., Groenendyk, J., Mehta, N. N., & Gourgari, E. (2019) · Clinical Cardiology · doi:10.1002/clc.23152 · Cited by 5
Second-Line Agents for the Treatment of Type 2 Diabetes and Prevention of CKD
Yu, M., & Kim, S. H. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10361016 · Cited by 5
Dobbins, R. L., Hussey, E. K., O'Connor‐Semmes, R. L., Andrews, S. M., Tao, W. X., Wilkison, W. O., Cheatham, B., Katare, S., & Barkate, H. V. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00502-0 · Cited by 5
Supakul, S., Nishikawa, Y., Teramura, M., & Takase, T. (2022) · Medicina · doi:10.3390/medicina58060815 · Cited by 5
Gori, M., D’Elia, E., Sciatti, E., & Senni, M. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.04 · Cited by 5
The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors
Kugathasan, L., Dubrofsky, L., Advani, A., & Cherney, D. Z. I. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2159810 · Cited by 5
“Patients with prediabetes or diabetes PRE-D [21] Age: 30–70 years BMI ≥25 kg/m(2) HbA1c: 5.”
BackgroundInfluentialSelim, A. M. A., Zolty, R., & Chatzizisis, Y. S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.011 · Cited by 5
“It also acts as an osmotic diuretic that reduces body weight and blood pressure (Kovacs et al., 2014; Tikkanen et al., 2015).”
BackgroundNew and developing pharmacotherapies for hypertension
Höcht, C., Allo, M. Á., Polizio, A. H., Moretton, M. A., Carranza, A., Chiappetta, D. A., & Choi, M. R. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2105204 · Cited by 5
Ye, Z., Li, H., Lü, H., Su, Q., & Li, L. (2017) · Oncotarget · doi:10.18632/oncotarget.22959 · Cited by 5
“Among them, type 2 diabetes mellitus complicated with hypertension is a common clinical disease [7, 8].”
BackgroundSGLT2 inhibitors: not just another glucose-lowering agent
Sternlicht, H., & Bakris, G. L. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.217 · Cited by 5
Hitting the Sweet Spot: A Review of SGLT2i in Cardiovascular Medicine
Zayyad, Z. A., Gupta, N., Roy, A., Kalagara, S., Mishra, A., Salem, E., Seshadri, S. R., Gichi, D., Hammad, B., Ene, A., et al. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00436-2 · Cited by 4
Belančić, A., Şener, Y. Z., Vučković, M., Blais, J. E., Fajkić, A., Sher, E. K., Radić, M., & Radić, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70378 · Cited by 4
Semirani-Nezhad, D., Roozbehi, K., Moghadam, A. S., Ebrahimi, E., Salehi, K., Hashempoor, A., Shamshiri, S., Azardar, T., Sabri, M., Moradi, A., et al. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200569 · Cited by 4
“Neeta B. Amin and others found that different doses of ertugliflozin (1, 5, 25 mg) lower BP by varying degrees in patients with diabetes and high BP. SGLT2 inhibitors ’ dose-dependent impacts were subsequently confirmed by other studies [23 – 25].”
Гоженко, А. І., Żukow, W., Olenovych, О. А., & Gozhenko, O. (2026) · Pedagogy and Psychology of Sport · doi:10.12775/pps.2026.31.69828 · Cited by 4
Ashjian, E. J., & Tingen, J. M. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000513336.46697.77 · Cited by 4
Management of hypertension in heart transplant recipients: an ongoing conundrum
Torres, J. D., & Krim, S. R. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001145 · Cited by 4
Maged, R., Sinha, M., Koneru, H. M., Sarwar, H., Bandi, V. V., Tarar, P., & Halawa, N. (2024) · Cureus · doi:10.7759/cureus.69623 · Cited by 4
“Other proposed mechanisms involved in the improvement of diastolic function in patients with HFpEF include decreased arterial stiffness [14] and a shift of energy consumption to ketone oxidation [15].”
Background[EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Scheen, A. J. (2015) · PubMed · Cited by 4
Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?
Kühn, A., Park, J., Ghazi, A., & Aroda, V. R. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0832-3 · Cited by 4
Turkish Society of Cardiology Consensus Paper on Evaluation and Treatment of Resistant Hypertension
Şahinarslan, A., Gazı, E., Aktöz, M., Özkan, Ç., Okyay, G. U., Elalmış, Ö. U., Belen, E., Bitigen, R. A., Derici, Ü., Tütüncü, N. B., et al. (2020) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2020.74154 · Cited by 4
“are speculated to result from its effects on BP and weight control (128).”
BackgroundSaad, M. S. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.08 · Cited by 4
“Other proposed theories for the reduction of heart failure with empagliflozin includes a potential beneficial effect on the metabolic syndrome through weight reduction (18,19), and modest reduction in systolic BP (13,16), as well and cardiac oxygen demand (20).”
BackgroundThe Growing Case for Use of SGLT2i in Heart Failure
Ha, C., & Wende, A. R. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.01.003 · Cited by 4
“(9) examined the hypothesis that SGLT2i may have beneficial effects in nondiabetic HFpEF, extending what was previously observed in patients with diabetes (1,10) and experimental models of pressure overload-induced heart failure model (6).”
BackgroundSaeed, S., Ali, A. M., Mahmoud, M. A., & Nilsson, P. M. (2023) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.39.3.7666 · Cited by 4
The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
Gala, D., Botros, F., & Makaryus, A. N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45204 · Cited by 3
Emerging Role of Sodium-Glucose Cotransporter-2 Inhibitors in Aortic Stenosis
Mazur, P. K., Kopytek, M., & Natorska, J. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101595 · Cited by 3
Sridharan, K., & Sivaramakrishnan, G. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103452 · Cited by 3
Ma, Y., Li, W., Liu, Y., & Li, L. (2024) · American Journal of Translational Research · doi:10.62347/lxjb8350 · Cited by 3
Panda, P., Mohapatra, R., & Samantaray, B. (2024) · Current Drug Research Reviews · doi:10.2174/0125899775332399240806101923 · Cited by 3
Sodium-glucose cotransporter-2 inhibitors: Moving beyond the glycemic treatment goal
Garodia, N., Gupta, V., Canovatchel, W. J., Lokesh, B., & Santani, R. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_85_17 · Cited by 3
“in rapid lowering of blood pressure in patients with T2DM and comorbid hypertension.[86,87] Data from pooled analysis of”
BackgroundJimba, T., Kaneko, H., Suzuki, Y., Okada, A., Azegami, T., Ko, T., Fujiu, K., Morita, H., Takeda, N., Hayashi, K., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf156 · Cited by 3
Kumar, S., Talwalkar, P., Das, S., & Goswami, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_161_17 · Cited by 3
“Furthermore, 24-h ambulatory BP monitoring was used and the modest reductions in blood pressure were not associated with increased heart rate.[53-56]”
MethodSodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure
Imprialos, K. P., Stavropoulos, K., & Papademetriou, V. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.004 · Cited by 3
Kameda, R., Nomoto, H., Cho, K. Y., Kawata, S., Omori, K., Takeuchi, J., Nagai, S., Kurihara, Y., Aoki, S., Nakamura, A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034883 · Cited by 3
Merész, G., Szabó, S. S., Dóczy, V., Hölgyesi, Á., & Szakács, Z. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.31690 · Cited by 3
The revolution of the anti-diabetic drugs in cardiology
Verdecchia, P., Angeli, F., Cavallini, C., Aita, A., Turturiello, D., & Reboldi, G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa084 · Cited by 3
“This effect was also confirmed by the use of ambulatory blood pressure monitoring for 24h.(11) The decrease in HbA1C is about 0.”
MethodA Review of Sodium Glucose Co transporter 2 (SGLT2) Inhibitors for Type 2 Diabetes Mellitus
Wong, E. (2016) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2016.04.00070 · Cited by 3
“These agents provide modest weight loss as the result of increased loss of urinary glucose and reduction in blood pressure by means of osmotic diuresis effects [5].”
BackgroundDiabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
Trojanowska-Grigoriew, M., & Majkowska, L. (2016) · Clinical Diabetology · doi:10.5603/dk.2016.0011 · Cited by 3
Dasgupta, K., Sapir‐Pichhadze, R., & Khan, N. A. (2017) · Journal of Clinical Hypertension · doi:10.1111/jch.13151 · Cited by 3
Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
Nissaisorakarn, P., Pavlakis, M., & Aala, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.03.001 · Cited by 3
Dissanayake, H. A., Dilrukshi, S., Ratnasamy, V., Soysa, P., Samarathunga, T., Bandara, P., Silva, L. D., & Katulanda, P. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.11.005 · Cited by 3
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Khan, S. H., & Weir, M. R. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_3 · Cited by 2
Özgöl, İ., YİĞİT, E., Yıldız, C., Karabulut, D., Çağlar, F. N. T., Bicakhan, B., Yücel, C., Ketenciler, S., Ay, A., & Yiğit, Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207395 · Cited by 2
“…7028 patients reported increases in LDL-C and HDL-C alongside TG reduction [8], a pooled analysis of ten RCTs showed a 4.5–6.5% rise in LDL-C [41], and other short-term studies have also reported heterogeneous effects, with modest increases in LDL-C and variable changes in TC, HDL-C, and TG [42].”
InfluentialSattar, O. I. A., Abuseada, H. H. M., Emara, M. S., Selim, I., & Ali, M. F. (2026) · BMC Chemistry · doi:10.1186/s13065-026-01726-z · Cited by 2
“The chemical formula is (2 S ,3 R ,4 R ,5 S ,6 R )−2-[4-chloro-3-[[4-[(3 S )-oxolan-3-yl] oxyphenyl]methyl]phenyl])6-(hydroxymethyl)oxane-3,4,5-triol.”
Personalized Diabetes Therapy Part 2—Individual Diabetes Treatment (Standard of Care Plus, SOC+)
Jantz, J., & Pfützner, A. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16040229 · Cited by 2
Steen, O., & Goldenberg, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.11.008 · Cited by 2
RetractedNan, G., Yang, C. B., & Jia, Z. (2025) · Advances in Interventional Cardiology · doi:10.5114/aic.2025.151600 · Cited by 2
“For instance, 12 weeks of treatment with 10 mg/day and 25 mg/day of empagliflozin respectively led to –3.44 mm Hg and –4.16 mm Hg decreases in systolic blood pressure and –1.36 mm Hg and –1.72 mm Hg decreases in diastolic blood pressure in patients with type 2 diabetes and hypertension [6].”
Influential
Metadata
- Authors
- Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J.
- Affiliations
- Helsinki University Hospital (FI)
- Boehringer Ingelheim (Finland) (FI)
- Boehringer Ingelheim (Germany) (DE)
- inVentiv Health Clinical (CA)
- Corresponding author
- Tikkanen, Ilkka
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-30
- Volume
- 38
- Issue
- 3
- Pages
- 420-428
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2138173919
- Cited by
- 468
- References
- 35
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 27 · 2023: 41 · 2022: 39 · 2021: 38 · 2020: 41 · 2019: 50 · 2018: 44 · 2017: 52 · 2016: 53 · 2015: 31 · 2014: 3
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, type 2 diabetes, hypertension, blood pressure reduction, SGLT2 inhibitors, ambulatory blood pressure monitoring, glycemic control, HbA1c, tolerability, adverse events, dose comparison, antihypertensive therapy, renin-angiotensin system blockade
- MeSH terms
- Analysis of Variance, Antihypertensive Agents, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Administration Schedule, Female, Glucosides, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.